OrbiMed’s Eledon Pharmaceuticals ELDN Stock Holding History

OrbiMed’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-73,650	Closed	-$1.1M	–	167
2020 Q4	$1.1M	Sell	73,650 -103,201	-58%	-$1.97M	0.01%	148
2020 Q3	$54.4M	Hold	176,851	–	–	0.68%	43
2020 Q2	$1.46M	Hold	176,851	–	–	0.02%	131
2020 Q1	$1.24M	Hold	176,851	–	–	0.02%	131
2019 Q4	$1.85M	Hold	176,851	–	–	0.03%	120
2019 Q3	$1.97M	Hold	176,851	–	–	0.04%	108
2019 Q2	$3.21M	Buy	176,851 +35,900	+25%	+$1.57M	0.05%	117
2019 Q1	$10.2M	Hold	140,951	–	–	0.16%	90
2018 Q4	$4.06M	Hold	140,951	–	–	0.08%	107
2018 Q3	$11.8M	Hold	140,951	–	–	0.14%	106
2018 Q2	$17.8M	Hold	140,951	–	–	0.21%	98
2018 Q1	$12.8M	Hold	140,951	–	–	0.16%	96
2017 Q4	$10.3M	Hold	140,951	–	–	0.13%	103
2017 Q3	$13.2M	Hold	140,951	–	–	0.13%	100
2017 Q2	$14.8M	Buy	+140,951	New	+$14.4M	0.16%	90

Other funds holding ELDN

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

OrbiMed's ELDN Position: Q1 2021 in Review

OrbiMed sold out of Eledon Pharmaceuticals (ELDN) in Q1 2021, closing a stake of 73,650 shares — an estimated $1.1M sold.

OrbiMed first reported a position in ELDN in Q2 2017 and held it in 15 quarters. The position peaked at $54.4M in Q3 2020. 34 funds tracked by Wall St. Rank hold ELDN as of Q1 2021.

OrbiMed reported no remaining Eledon Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
OrbiMed sold 73,650 Eledon Pharmaceuticals shares in Q1 2021, an estimated $1.1M.
OrbiMed first reported a position in Eledon Pharmaceuticals in Q2 2017 and held it in 15 quarters.
OrbiMed's Eledon Pharmaceuticals position peaked at $54.4M in Q3 2020.
34 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q1 2021.

Based on OrbiMed's 13F filing for Q1 2021, filed 17 May 2021.